Matthew Meyerson
A5056373767- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- HER2/EGFR in Cancer Research
- Viral-associated cancers and disorders
- Epigenetics and DNA Methylation
- Fibroblast Growth Factor Research
- Cancer-related molecular mechanisms research
- Genetic factors in colorectal cancer
- Glioma Diagnosis and Treatment
- Lung Cancer Research Studies
- Molecular Biology Techniques and Applications
- Genomic variations and chromosomal abnormalities
- Cancer-related Molecular Pathways
- Medical Imaging and Pathology Studies
- RNA Interference and Gene Delivery
- Cancer, Hypoxia, and Metabolism
- Heat shock proteins research
- Renal cell carcinoma treatment
- Gene expression and cancer classification
- Sarcoma Diagnosis and Treatment
Weatherford College
2022-2025
Harvard University
2015-2024
Broad Institute
2015-2024
Dana-Farber Cancer Institute
2015-2024
Dana-Farber Brigham Cancer Center
2005-2024
Yale University
2013-2023
Massachusetts Institute of Technology
2012-2023
Boston University
2012-2023
Brigham and Women's Hospital
2012-2022
Harvard University Press
2007-2022
We analysed primary breast cancers by genomic DNA copy number arrays, methylation, exome sequencing, messenger RNA microRNA sequencing and reverse-phase protein arrays. Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes demonstrated the existence of four main cancer classes when combining data from five platforms, each which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA...
Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR found 15of 58 unselected tumors from Japan 1 61 United States. Treatment with inhibitor gefitinib (Iressa) causes tumor regression some patients NSCLC, more frequently Japan. additional samples U.S. who responded to therapy a adenocarcinoma line that was hypersensitive inhibition by gefitinib, but not...
We performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array- sequencing-based technologies. Uterine serous tumours ∼25% high-grade endometrioid had extensive copy number alterations, few DNA methylation changes, low oestrogen receptor/progesterone receptor levels, frequent TP53 mutations. Most alterations or mutations, but mutations in PTEN, CTNNB1, PIK3CA, ARID1A KRAS novel the SWI/SNF chromatin remodelling complex gene ARID5B....
Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non-small-cell lung cancer who a response to anilinoquinazoline EGFR inhibitors. Despite dramatic responses such inhibitors, most ultimately relapse. The mechanism drug resistance is unknown. Here we report case patient EGFR-mutant, gefitinib-responsive, advanced had relapse after two years complete remission during treatment gefitinib. DNA sequence his tumor biopsy specimen at...
We describe methods with enhanced power and specificity to identify genes targeted by somatic copy-number alterations (SCNAs) that drive cancer growth. By separating SCNA profiles into underlying arm-level focal alterations, we improve the estimation of background rates for each category. additionally a probabilistic method defining boundaries selected-for regions user-defined confidence. Here detail this revised computational approach, GISTIC2.0, validate its performance in real simulated datasets.
Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment disease. As part The Cancer Genome Atlas project, we report here an integrated analysis 131 urothelial carcinomas to provide comprehensive landscape molecular alterations. There were statistically significant recurrent mutations in 32 genes, including multiple genes involved cell-cycle regulation,...
Highlights•Alteration map of 10 signaling pathways across 9,125 samples from 33 cancer types•Reusable, curated pathway templates that include a catalogue driver genes•57% tumors have at least one potentially actionable alteration in these pathways•Co-occurrence alterations suggests combination therapy opportunitiesSummaryGenetic control cell-cycle progression, apoptosis, and cell growth are common hallmarks cancer, but the extent, mechanisms, co-occurrence differ between individual tumor...
We have generated a molecular taxonomy of lung carcinoma, the leading cause cancer death in United States and worldwide. Using oligonucleotide microarrays, we analyzed mRNA expression levels corresponding to 12,600 transcript sequences 186 tumor samples, including 139 adenocarcinomas resected from lung. Hierarchical probabilistic clustering data defined distinct subclasses adenocarcinoma. Among these were tumors with high relative neuroendocrine genes type II pneumocyte genes, respectively....
Head and neck squamous cell carcinoma (HNSCC) is a common, morbid, frequently lethal malignancy. To uncover its mutational spectrum, we analyzed whole-exome sequencing data from 74 tumor-normal pairs. The majority exhibited profile consistent with tobacco exposure; human papillomavirus was detectable by DNA infected tumors. In addition to identifying previously known HNSCC genes (TP53, CDKN2A, PTEN, PIK3CA, HRAS), our analysis revealed many not implicated in this At least 30% of cases...
Liver cancer has the second highest worldwide mortality rate and limited therapeutic options. We analyzed 363 hepatocellular carcinoma (HCC) cases by whole-exome sequencing DNA copy number analyses, we 196 HCC methylation, RNA, miRNA, proteomic expression also. mutation analysis identified significantly mutated genes, including LZTR1, EEF1A1, SF3B1, SMARCA4. Significant alterations or downregulation hypermethylation in genes likely to result metabolic reprogramming (ALB, APOB, CPS1) were...